2020 Volume 29 Issue 3 Pages 181-187
The recent advances in next-generation sequencing have enabled the clinical application of cancer genome analysis in conjunction with artificial intelligence. In 2019, the cancer genome core base hospitals were established. In June 2019, two kinds of cancer-panels were covered by public insurance. Genome-based precision medicine has shown rapid advances and every core hospital makes every effort to catch up with the developments. However, there are still several constraints, such as the overall system, budget, and human resources.
While grappling with these issues, what can we do for patients with refractory brain tumors, including glioblastoma?
In this article, I would like to discuss the current status and the future perspectives of cancer genome precision medicine in the context of brain tumors.
